Postmenopausal Bleeding

Summary

Postmenopausal bleeding (PMB) is any uterine bleeding occurring 12 months or more after menopause and always warrants evaluation to exclude malignancy. While most cases result from atrophic endometrium or vaginitis due to estrogen deficiency, other causes include endometrial hyperplasia, polyps, hormone therapy, and endometrial carcinoma. Transvaginal ultrasound is the first-line investigation, with endometrial biopsy indicated if the thickness exceeds 4 mm or bleeding persists. Management depends on the cause, ranging from topical estrogen for atrophy to surgery for malignancy.

Overview

Definition:

 Postmenopausal bleeding (PMB) refers to any uterine bleeding that occurs ≥12 months after the final menstrual period due to age-related ovarian follicular depletion and resulting hypoestrogenism.
It is a common gynecologic presentation and always warrants evaluation, as 5–10% of women with PMB have endometrial carcinoma.

Epidemiology:

• PMB accounts for up to 5% of all gynecologic visits in postmenopausal women.

• The mean age at presentation is approximately 60 years.
  
  

Clinical Significance:

Although most causes are benign (especially atrophic changes), endometrial carcinoma must be excluded in every case.

Etiology of PMB

1. Atrophic Vaginitis

• Most common cause of PMB (≈60–80%)

• Pathophysiology: Estrogen deficiency → thinning of vaginal and endometrial epithelium → increased fragility and inflammation → spotting or bleeding. 

• Symptoms:

• Vaginal dryness and itching

• Dyspareunia

• Watery or yellow vaginal discharge

• Urinary urgency or recurrent UTIs

• Signs (on speculum exam):

• Pale, dry, thin mucosa

• Loss of rugae

• Petechiae or small fissures

• Treatment:

• Local vaginal estrogen (cream, tablet, or ring)

• Lubricants and vaginal moisturizers for symptomatic relief

• Systemic hormone therapy (only if there are additional menopausal symptoms and no contraindications)
  
  

 

2. Endometrial Hyperplasia

• Definition: Excessive proliferation of endometrial glands due to unopposed estrogen stimulation.

• Risk Factors:

• Obesity (peripheral conversion of androgens → estrogen)

• Chronic anovulation (e.g., PCOS)

• Estrogen-only HRT

• Estrogen-producing ovarian  tumors  (granulosa/theca cell tumors)

• Tamoxifen use

• Early menarche or late menopause
  
  

• Diagnosis:

• Transvaginal ultrasound (TVUS): Endometrial thickness >4 mm in a woman with PMB is abnormal.

• Endometrial biopsy: Gold standard; identifies simple/complex hyperplasia ± atypia.

• Management:

• Without atypia: Cyclic or continuous progestin therapy (e.g., medroxyprogesterone acetate, LNG-IUS) or observation.

• With atypia / complex hyperplasia: Total hysterectomy (TAH ± BSO) recommended.

 

3. Endometrial Carcinoma

• Must be excluded in all cases of PMB.

• Symptoms: 

• Postmenopausal painless vaginal bleeding or spotting (most common)

• Late signs: pelvic pain, weight loss, bladder or bowel symptoms

• Risk Factors:

• Unopposed estrogen exposure, obesity, diabetes, nulliparity, Lynch syndrome, tamoxifen use.

• Diagnosis:

• TVUS: Endometrial stripe >4 mm

• Endometrial biopsy: Confirms malignancy

• Hysteroscopy ± D&C: For direct visualization and sampling

• Treatment:

• Stage I–II: Total abdominal hysterectomy with bilateral salpingo-oophorectomy (TAH + BSO)

• Advanced disease: Add pelvic ± para-aortic lymphadenectomy, radiotherapy, and/or chemotherapy (usually carboplatin + paclitaxel)

4. Endometrial & Cervical polyps

• Often benign; can cause intermittent bleeding.

• Diagnosis: TVUS or hysteroscopy.

• Management: Hysteroscopic polypectomy (also diagnostic).

• Tamoxifen therapy increases risk for endometrial polyps and cystic changes.

5. Hormonal therapy (e.g., Tamoxifen)

• Sequential HRT: Withdrawal bleeding is expected.

• Continuous combined HRT: Irregular bleeding may occur in the first 6 months; if persistent beyond 6–12 months, evaluate as PMB.

6. Other Causes:

• Genital tract malignancies: Cervical, vaginal, vulvar, or fallopian tube cancer.

• Urologic sources: Urethral caruncle, urethral prolapse, or bladder carcinoma.

• Trauma or foreign body: Especially pessary-related.

• Coagulopathies or anticoagulant therapy (less common).

Evaluation of PMB

1. History

• Onset, duration, amount, and pattern of bleeding

• HRT use or recent discontinuation

• Associated symptoms (pain, discharge, urinary or GI symptoms)

• Past gynecologic and obstetric history

• Medications (anticoagulants, tamoxifen)

 

2. Physical Examination

• Speculum exam: Inspect for vaginal atrophy, lesions, or cervical pathology.

• Bimanual exam: Evaluate uterine size, mobility, and adnexal masses.

• Rectovaginal exam: If malignancy is suspected.

 

3. Investigations

Management overview